During the session, renowned experts—including Prof. @johanneslevin.bsky.social (LMU), Prof. Jason Hassenstab @ctrlab.org and Prof. Andre Strydom (King's College London)—reviewed the latest scientific advances in the field.

Alzheimer ist die häufigste Todesursache bei Menschen mit Down-Syndrom. Die Alzheimer Forschung Initiative hat hierzu ein neues Video veröffentlicht. Wir freuen uns sehr, dass die spezialisierte Ambulanz an der Neurologie der LMU München erwähnt wird. 👉 Zum Video: youtu.be/UovdbwD44F0?...

It was a great honor to host the #GENFI summer meeting 2025. Two days of excellent talks and inspiring discussions. Thanks for coming to Munich and safe travels to everyone.

¡¡Día histórico para el Betis!! ¿Cómo va a quedar esto? ¡Vamos con todooo! 💚⚽️ What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️

I have a new favorite conference: dsad-adad.com See you in Barcelona next year for the 3rd edition of DSAD-ADAD.

Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant delay in the onset of symptoms.

TOPAS-MSA is launching in Japan. The investigator meeting took place yesterday and today in Yokohama. Japan’s strong tradition in MSA research and the outstanding dedication of the trial sites created an exciting environment. We’re thrilled to have you on board. clinicaltrials.gov/study/NCT065...

We did it and now it is published: A highly Lewy-fold selective and quantitative Synuclein Aggregate Amplification Assay (SAA). Huge thanks to the amazing teams at MODAG GmbH, LMU Munich, and Bologna University! rdcu.be/eaISM

The TOPAS-MSA study investigating emrusolmin for disease modification in Multiple System Atrophy (MSA) is starting in Europe. Impressions from the investigator meeting in Barcelona (Spain). www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/

The risk of developing dementia may be much higher than previously thought, a study published in the journal Nature Medicine has found.

One of the largest health insurance companies in Germany shows interest in Alzheimer’s disease in individuals with Down Syndrome: www.aok.de/pk/magazin/k...

So well deserved. An example to follow for all of us.

Betis is starting the year en Aragón. Vamooos!! www.abc.es/deportes/alf...

Still on my 25-year crusade to end all two-sided alpha testing in superiority trials. It's something simulating clinical trials brings out as just plain silly.

A interesting body of commentary from key people on this critically important topic. Definitely worth a read. Is removing substantial amyloid plus meeting safety targets enough to approve a treatment for #Alzheimer's? #ENDALZ www.alzforum.org/news/researc...

Difficult match in complicated moment for the most special club in Spanish football. Will we see Isco back on the pitch? www.abc.es/deportes/alf...

Much needed attention for DS-AD. web.de/magazine/ges...

🎨 In case anyone need… The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏! Check it out 👇 bioart.niaid.nih.gov

International break is over. Día del Betis! «Los sentimientos estarán a flor de piel» www.abc.es/deportes/alf... Vamooos!! Mucho Betis!

Day two on @bsky.app and I'll go ahead say I'm LOVING IT. Fellow #scientists and #Alzheimer's and #ADRD peeps: Tell everyone you know to get on over here! The skies are blue once again!